CSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management

Bulletin Express

Yesterday

CSPC Pharmaceutical Group Limited (CSPC Pharma) has officially initiated the Phase I clinical trial of its investigational SYH2092 injection at the first study centre in China. The trial targets adult participants with overweight or obesity and follows the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration in August 2026.

SYH2092 is an amylin receptor agonist engineered for enhanced target activation and extended in-vivo half-life through fatty-acid modification. Preclinical studies indicated superior receptor agonistic activity, strong weight-reduction efficacy, and prolonged maintenance of weight loss compared with other amylin analogues currently in development.

The Phase I study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics after a single dose in healthy volunteers. Participant recruitment and screening are in progress.

Beyond weight management, SYH2092 is also positioned to address glycaemic control in adults with type 2 diabetes mellitus, aligning with CSPC Pharma’s strategic focus on metabolic disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1187521439"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187521439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187521439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187521439","market":"hk","top_or_hot":-1,"title":"CSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has officially initiated the Phase I clinical trial of its investigational SYH2092 injection at the first study centre in China. The trial targets adult participants with overweight or obesity and follows the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration in August 2026.</p>\n<p>SYH2092 is an amylin receptor agonist engineered for enhanced target activation and extended in-vivo half-life through fatty-acid modification. Preclinical studies indicated superior receptor agonistic activity, strong weight-reduction efficacy, and prolonged maintenance of weight loss compared with other amylin analogues currently in development.</p>\n<p>The Phase I study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics after a single dose in healthy volunteers. Participant recruitment and screening are in progress.</p>\n<p>Beyond weight management, SYH2092 is also positioned to address glycaemic control in adults with type 2 diabetes mellitus, aligning with CSPC Pharma’s strategic focus on metabolic disorders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-31 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has officially initiated the Phase I clinical trial of its investigational SYH2092 injection at the first study centre in China. The trial targets adult participants with overweight or obesity and follows the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration in August 2026.</p>\n<p>SYH2092 is an amylin receptor agonist engineered for enhanced target activation and extended in-vivo half-life through fatty-acid modification. Preclinical studies indicated superior receptor agonistic activity, strong weight-reduction efficacy, and prolonged maintenance of weight loss compared with other amylin analogues currently in development.</p>\n<p>The Phase I study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics after a single dose in healthy volunteers. Participant recruitment and screening are in progress.</p>\n<p>Beyond weight management, SYH2092 is also positioned to address glycaemic control in adults with type 2 diabetes mellitus, aligning with CSPC Pharma’s strategic focus on metabolic disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1187521439","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187521439","pubTimestamp":1788177685,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has officially initiated the Phase I clinical trial of its investigational SYH2092 injection at the first study centre in China. The trial targets...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团开始用于肥胖管理的新型胰淀素受体激动剂SYH2092的I期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has officially initiated the Phase I clinical trial of its investigational SYH2092 injection at the first study centre in China. The trial targets adult participants with overweight or obesity and follows the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration in August 2026.\nSYH2092 is an amylin receptor agonist engineered for enhanced target activation and extended in-vivo half-life through fatty-acid modification. Preclinical studies indicated superior receptor agonistic activity, strong weight-reduction efficacy, and prolonged maintenance of weight loss compared with other amylin analogues currently in development.\nThe Phase I study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics after a single dose in healthy volunteers. Participant recruitment and screening are in progress.\nBeyond weight management, SYH2092 is also positioned to address glycaemic control in adults with type 2 diabetes mellitus, aligning with CSPC Pharma’s strategic focus on metabolic disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}